Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$74.45 USD

74.45
4,474,605

+0.96 (1.31%)

Updated May 15, 2024 04:00 PM ET

After-Market: $74.43 -0.02 (-0.03%) 6:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (145 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Integra's (IART) Q1 Earnings Match Estimates, Margins Down

Strong demand for Integra's (IART) diverse portfolio of leading brands and continued successful market adoption of CereLink contributes to its revenues.

Quest Diagnostics (DGX) Grows in Digital Pathology With New Deal

Quest Diagnostics' (DGX) pathology laboratories nationwide are set to get a boost with PathAI's AISight digital pathology image management system.

Shockwave Medical (SWAV) Q1 Earnings Beat, Revenues Rise Y/Y

Shockwave Medical's (SWAV) first-quarter results reflect robust revenue growth and gross margin expansion amid JNJ entering into a definitive agreement to acquire the company.

GE HealthCare (GEHC) Unveils Head-Only MR Scanner SIGNA MAGNUS

GE HealthCare's (GEHC) new SIGNA MAGNUS can delve deep into the brain's microstructure, microvasculature and function, providing researchers with a clearer picture of neurological diseases and disorders.

The Zacks Analyst Blog Highlights Alphabet, Netflix, Amazon, ServiceNow and Boston Scientific

Alphabet, Netflix, Amazon, ServiceNow and Boston Scientific are included in this Analyst Blog.

Nalak Das headshot

A Golden Opportunity to Enter U.S. Stock Markets: 5 Top Picks

We have narrowed our search to five U.S. corporate behemoths that have strong growth potential for 2024. These are: GOOGL, NFLX, AMZN, NOW, BSX.

Avanos (AVNS) Q1 Earnings & Revenues Surpass Estimates

Avanos' (AVNS) first-quarter results show strong bottom-line improvement along with decent growth in segmental revenues.

Surmodics (SRDX) Q2 Earnings Top Estimates, '24 View Up

Surmodics (SRDX) fiscal second-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate.

Hologic's (HOLX) Q2 Earnings Beat Estimates, 2024 View Up

Hologic's (HOLX) GYN Surgical Q2 performance was driven by strong results from MyoSure and Fluent Fluid Management.

Lantheus (LNTH) Q1 Earnings Surpass Estimates, Gross Margin Up

Lantheus' (LNTH) robust revenues from the majority of its segments drive its first-quarter performance.

DaVita (DVA) Q1 Earnings & Revenues Top Estimates, Margins Up

DaVita's (DVA) robust segmental revenues drive its first-quarter performance.

Bruker (BRKR) Q1 Earnings Surpass Estimates, Margins Decline

Bruker's (BRKR) BioSpin segment witnessed growth across biopharma, academic government and industrial research in the first quarter of 2024.

Teleflex (TFX) Q1 Earnings Beat Estimates, Margins Rise

Teleflex's (TFX) first-quarter 2024 results reflect growth across the majority of the company's product families in EMEA.

GE Healthcare's (GEHC) Revolution RT to Aid Cancer Treatment

GE Healthcare (GEHC) unveils Revolution RT, along with other upgrades, from its portfolio during the ESTRO 2024 Congress.

DENTSPLY SIRONA (XRAY) Q1 Earnings In Line, Revenues Decline Y/Y

DENTSPLY SIRONA's (XRAY) first-quarter 2024 results showcase a decline in year-over-year sales with an improved bottom line.

Zimmer Biomet (ZBH) Q1 Earnings Beat, Margins Expand

Each of Zimmer Biomet's (ZBH) geographic segments records strong year-over-year sales growth on a reported basis, as well as at CER.

Envista (NVST) Q1 Earnings Miss Estimates, Margins Down

Envista (NVST) registers a year-over-year decline in both segments in the first quarter of 2024.

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

Investors are optimistic about Quest Diagnostics (DGX) on strong legacy business growth.

Cardinal Health (CAH) Beats on Q3 Earnings, Ups '24 EPS View

Cardinal Health's (CAH) third-quarter fiscal 2024 results benefit from solid profit growth in Pharmaceutical and Specialty Solutions. The company raises its EPS guidance for fiscal 2024.

Baxter (BAX) Q1 Earnings Beat Estimates, '24 EPS View Raised

Baxter (BAX) reports better-than-expected first-quarter earnings and sales. BAX's quarterly results reflect solid demand for a range of its medically essential products.

BD (BDX) Q2 Earnings Surpass Estimates, FY24 View Revised

BD's (BDX) overall top line benefits from revenue growth in all segments and both geographic regions in the fiscal second quarter.

Accuray (ARAY) Q3 Earnings Lag Estimates, Gross Margin Contracts

Despite strength in radiation oncology, Accuray (ARAY) reports dismal third-quarter fiscal 2024 results.

Glaukos (GKOS) Q1 Earnings Miss Estimates, Revenues Up Y/Y

Glaukos' (GKOS) first-quarter 2024 results showcase growth in revenues while earnings miss the Zacks consensus Estimate. Loss at the operating level raises concern as well.

Here's Why You Should Retain STERIS (STE) Stock for Now

STERIS' (STE) strong prospects in the healthcare and pharmaceutical industries bode well for investors.

Merit Medical (MMSI) Q1 Earnings Top Estimates, Margins Up

Merit Medical (MMSI) benefits from revenue growth in both segments and the majority of its product categories within its Cardiovascular unit in the first quarter.